Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506083 | 0.97 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL6004566 | 0.97 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL24106500 | 0.97 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL3549863 | 0.92 | — | — | |
| SCHEMBL1110035 | 0.90 | OPRM1 (0.42) | ACE2OPRM1LMNACA1SPHK1 | |
| SCHEMBL25846504 | 0.90 | ACE2 (0.48) | ACE2OPRM1LMNACA1SPHK1 | |
| SCHEMBL25922596 | 0.90 | ACE2 (0.48) | ACE2OPRM1LMNACA1SPHK1 | |
| SCHEMBL20925024 | 0.90 | ACE2 (0.48) | ACE2OPRM1LMNACA1SPHK1 | |
| SCHEMBL4904464 | 0.86 | ACE2 (0.58) | ACE2OPRM1LMNACA1SPHK1 | |
| SCHEMBL2224388 | 0.85 | ACE2 (0.50) | ACE2OPRM1LMNASPHK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | ACE2 1713/4885OPRM1 75/4885LMNA 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.